|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Sanofi
|
|
gptkbp:business_model
|
biotech
|
|
gptkbp:ceo
|
Martin Babler
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
academic institutions
research institutions
biopharmaceutical companies
|
|
gptkbp:employees
|
approximately 100
|
|
gptkbp:focus
|
autoimmune diseases
|
|
gptkbp:founded
|
gptkb:2010
|
|
gptkbp:founder
|
Martin Babler
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Principia Biopharma
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
pending
granted
|
|
gptkbp:investment
|
gptkb:Foresite_Capital
gptkb:Sofinnova_Ventures
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
global
|
|
gptkbp:language_of_instruction
|
clinical candidates
preclinical candidates
|
|
gptkbp:leadership
|
experienced executives
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:mission
|
develop innovative therapies
|
|
gptkbp:partnership
|
gptkb:Sanofi
|
|
gptkbp:partnerships
|
pharmaceutical companies
research organizations
|
|
gptkbp:products
|
PR N1371
PR N2246
|
|
gptkbp:publishes
|
peer-reviewed journals
|
|
gptkbp:receives_funding_from
|
gptkb:Company
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_areas
|
neurology
rheumatology
dermatology
immunology
small molecule therapeutics
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
gptkb:psychologist
B-cell signaling
chronic spontaneous urticaria
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:symbol
|
PRNB
|
|
gptkbp:technology
|
proprietary platform
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:vision
|
transform patient care
|
|
gptkbp:website
|
www.principiabio.com
|
|
gptkbp:bfsParent
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:bfsLayer
|
4
|